‘Not foes': China to Aus amid nuclear build-up
Xi Jinping's envoy in Canberra says China and Australia are 'not foes', despite being embroiled in a regional rivalry and Beijing rapidly building up conventional and nuclear military capabilities.
Anthony Albanese has been facing domestic and international calls to boost the defence budget, with the US warning of a potentially 'imminent' threat from China in the Indo Pacific.
But the Prime Minister has resisted, making Australia an outlier in the West – a position highlighted by NATO's decision last week to dramatically hike military spending to 5 per cent of GDP.
Chinese ambassador Xiao Qian on Monday urged Mr Albanese to stay the course.
'Recently, some countries hyped up the so-called China threat narrative on occasions such as the Shangri-La Dialogue, G7 summit and NATO summit, proclaiming to significantly increase defence expenditures, and even incited Australia to follow suit,' Mr Xiao wrote in The Australian.
'Such rhetoric and actions are steeped in Cold War mentality, blatantly creating division, fuelling a global arms race as well as threatening world peace and stability, which warrants our high vigilance.
'By playing up international and regional tensions and slandering China's normal military build-up, these countries are merely seeking nothing but excuses to drastically grow their military spending, even arbitrarily reaching beyond its geographical scope and mandate.'
He accused 'certain countries' of trying to contain China because they 'fear fair competition' and 'cannot tolerate other countries from making progress'.
Mr Xiao's piece comes as Foreign Minister Penny Wong heads to Washington for a second meeting with her Quad counterparts within six months.
The Quad, made up of Australia, India, Japan and the US, is a partnership broadly seen as a check on China's economic and military might.
Earlier this month, US Defence Secretary Pete Hegseth warned China could invade the democratically self-governed island of Taiwan as early as 2027.
Such a move would deal a major blow to global supply of semiconductors – crucial components in modern tech – and massively disrupt vital trade routes.
'Let me be clear, any attempt by Communist China to conquer Taiwan by force would result in devastating consequences for the Indo-Pacific and the world,' Mr Hegseth told the Shangri La Dialogue.
'There's no reason to sugar-coat it. The threat China poses is real and it could be imminent.
'We hope not but certainly could be.'
Meeting with Deputy Prime Minister Richard Marles on the sidelines of the conference, he directly asked Australia to boost the defence spending to 3.5 per cent of GDP.
The Albanese government was quick to brush off the request, saying Australia would set its own military budget.
But days later, Mr Marles, who is also defence minister, admitted China's growing nuclear arsenal was driving 'security anxiety'.
'I mean, we've made no secret of the fact that we have a security anxiety in relation to China that's principally driven by the very significant conventional military build-up that China is engaging in, and, for that matter, a nuclear build-up that China is engaging in,' he told reporters.
'We've made that clear to China itself.'
As of mid-2024, China's operational nuclear warheads exceeded 600, according to the US Department of Defence.
That was nearly triple what the country was estimated to have in 2020.
More recently, Mr Marles refused to say whether three Chinese warships that circumnavigated Australia earlier this year targeted cities when they carried out exercises off the country's vast coastline.
Appearing at New Corp's Defending Australia Summit, he said was asked point blank if the ships rehearsed strikes on Australian cities or onshore facilities.
'Look, I do know the answer to the question,' he said.
'I don't think it's appropriate or helpful for me in this situation to speculate about it for a range of reasons … and the most significant being what we did with the Chinese task group was to engage in an unprecedented level of surveillance on that task group.
'So we do know exactly what they were doing and exactly what they're rehearsing.
'For me to start talking about that obviously reveals our surveillance capabilities, which is why I'm reluctant to.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
33 minutes ago
- Associated Press
Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions
Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting request to continue discussions on path forward for accelerated approval of TXM for bird flu Phase 2 study protocol submitted to HREC to evaluate ratutrelvir in newly diagnosed COVID patients, with extensions to measure disease rebound and development of Long COVID NEWTOWN, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ('Traws Pharma', 'Traws' or 'the Company'), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced multiple regulatory submissions related to its antiviral pipeline. Tivoxavir marboxil A proposed Phase 2 dose-ranging, non-inferiority study will evaluate the effects of tivoxavir marboxil (TXM), a potential best in class CAP-dependent endonuclease inhibitor, compared to XOFLUZA®, in patients infected with seasonal influenza. A separate single arm will evaluate the effects of TXM in patients infected with H5N1 bird flu. The proposed study has been submitted for Human Research Ethics Committee (HREC) review and is expected to enroll subjects in Australia and selected countries in Southeast Asia (SE Asia) with high rates of human bird flu infections. 'This combined study, evaluating the effects of TXM in seasonal and bird flu patients, could support the broad use of TXM against multiple influenza strains,' commented Robert R. Redfield, MD, Chief Medical Officer for Traws Pharma and former Director of the U.S. Centers for Disease Control and Prevention (CDC). 'The high rates of animal-to-human transmission of bird flu in SE Asia should allow us to evaluate the efficacy of TXM in this important clinical setting, adding to our robust pre-clinical efficacy results of TXM against bird flu.' Also, as a follow up to recent Pre-IND FDA interactions on TXM, Traws submitted briefing materials for a Type D meeting to enable further FDA dialog on a potential path to accelerated approval for bird flu. 'We are continuing to discuss with the FDA the applicability of the Animal Rule and other routes that could support an accelerated approval of TXM for bird flu,' commented C. David Pauza, PhD, Chief Science Officer for Traws Pharma. 'We look forward to continuing positive interactions with the Agency.' Ratutrelvir A proposed Phase 2 non-inferiority study will evaluate the effects of ratutrelvir, a potential best in class protease inhibitor that does not require ritonavir co-administration, compared to PAXLOVID®, in newly diagnosed COVID patients. The proposed study that has been submitted for HREC review is intended to enroll patients on a 10-day treatment regimen for ratutrelvir compared to the approved 5-day regimen for PAXLOVID®. In addition to efficacy and safety endpoints, the proposed study will also evaluate the rates of disease rebound as well as the incidence of Long COVID. A separate single arm will evaluate the safety and efficacy of ratutrelvir in newly diagnosed COVID patients who are ineligible for treatment with PAXLOVID®. 'A significant population of patients who are at risk for poor outcomes from COVID are ineligible for PAXLOVID®. In addition, rebound infections and prevention of the development of Long COVID are unaddressed by existing therapies. We believe ratutrelvir has the potential to overcome these issues,' commented Dr. Redfield. 'Our proposed Phase 2 study is expected to highlight the differentiating attributes of ratutrelvir compared to existing approved therapies.' 'Today's announcements demonstrate our commitment to rapidly advance our antiviral portfolio,' commented Iain D. Dukes, MA, DPhil, Interim Chief Executive Officer for Traws Pharma. 'We look forward to delivering these potentially vital medicines to patients.' About Tivoxavir Marboxil Tivoxavir marboxil (TXM) is an investigational oral, small molecule CAP-dependent endonuclease inhibitor designed to be administered as a single-dose for the treatment of bird flu and seasonal influenza. It has potent in vitro activity against a range of influenza strains in preclinical studies, including a human isolate of the highly pathogenic avian flu H5N1 (bird flu). Consistent, positive preclinical data from three animal species indicate that a single dose of TXM demonstrated a therapeutic effect against H5N1 bird flu. Seasonal influenza represents an estimated multi-billion dollar antiviral market opportunity, largely driven by global health organizations, practice guidelines and government tenders1,2, with upside potential from potential pandemic flu outbreaks including H5N1 bird flu. We believe that these data support further development of TXM as a treatment for bird flu. About Ratutrelvir Ratutrelvir is an investigational oral, small molecule Mpro (3CL protease) inhibitor designed to be a broadly acting treatment for COVID-19 that is used without ritonavir. It has demonstrated in vitro activity against a range of COVID-19 strains. Preclinical and Phase 1 studies show that ratutrelvir does not require co-administration with a metabolic inhibitor, such as ritonavir, which could avoid ritonavir-associated drug-drug interactions3, and potentially enable wider patient use. Phase 1 data also show that ratutrelvir's pharmacokinetic (PK) profile demonstrated maintenance of target blood plasma levels approximately 13 times above the EC50 using the target Phase 2 dosing regimen of 600 mg/day for ten days, which may also reduce the likelihood of clinical rebound and, consequently, reduce the risk for Long COVID4. Industry data indicate that COVID treatment represents a potential multi-billion dollar market opportunity5,6. Source information: Third-party products mentioned herein are the trademarks of their respective owners. About Traws Pharma, Inc. Traws Pharma is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to meet real world challenges in the treatment of viral diseases. We are advancing novel investigational oral small molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Tivoxavir marboxil is in development as a single dose treatment for bird flu and seasonal influenza, targeting the influenza cap-dependent endonuclease (CEN). Ratutrelvir is in development as a ritonavir-independent COVID treatment, targeting the Main protease (Mpro or 3CL protease). Traws is actively seeking development and commercialization partners for its legacy clinical oncology programs, rigosertib and narazaciclib. More details can be found on Traws' website at For more information, please visit and follow us on LinkedIn. Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties including statements regarding the Company, its business and product candidates, including the potential opportunity, benefits and the regulatory plans for tivoxavir marboxil. The Company has attempted to identify forward-looking statements by terminology including 'believes', 'estimates', 'anticipates', 'expects', 'plans', 'intends', 'may', 'could', 'might', 'will', 'should', 'preliminary', 'encouraging', 'approximately' or other words that convey uncertainty of future events or outcomes. Although Traws believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including our ability to proceed with our proposed clinical trials and to enroll sufficient subjects in such studies and trials, the success and timing of Traws' clinical trials, our ability to take advantage of expedited regulatory pathways for tivoxavir marboxil, our ability to obtain regulatory approval of tivoxavir marboxil and ratutrelvir, the expectations of our interactions with regulatory authorities, including the FDA, the Human Research Ethics Committee (HREC) and other international regulatory agencies, market conditions, regulatory requirements, changes in government regulation, the extent of the spread and threat of bird flu, seasonal influenza and COVID, and those discussed under the heading 'Risk Factors' in Traws' filings with the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this release speak only as of its date. Traws undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except to the extent required by law. Traws Pharma Contact: Nora Brennan Traws Pharma, Inc. [email protected] Investor Contact: John Fraunces LifeSci Advisors, LLC 917-355-2395 [email protected]


Washington Post
36 minutes ago
- Washington Post
America owes its Afghan partners more than this
Douglas Lute is a retired U.S. Army lieutenant general and a former U.S. ambassador to NATO. Thomas Warrick is a former Department of Homeland Security deputy assistant secretary for counterterrorism policy and a senior fellow for the Future of DHS Project at the Atlantic Council. As the Senate takes up the House-initiated One Big Beautiful Bill Act, it can uphold America's honor and national interest by protecting the Afghans who served alongside our military and civilians in the two decades following al-Qaeda's attack on Sept. 11, 2001.
Yahoo
an hour ago
- Yahoo
NATO fund backs biotech startup in push to counter biological threats
By Supantha Mukherjee STOCKHOLM (Reuters) -The NATO Innovation Fund has made its first investment in a biotechnology company, it said on Monday, seeking to enhance defences against biological threats The fund is co-leading a $35 million fundraising round for Portal Biotech, which uses protein sequencing to detect engineered threats and defend against biological warfare. UK-based Portal Biotech's capability is essential for biosecurity defence and security, said Ana Bernardo-Gancedo, senior associate at NATO Innovation Fund. "We believe that it is absolutely imperative that we are able to detect, monitor and create countermeasures," she said. The fund, created in 2022 after the Russian invasion of Ukraine, plans to invest more than $1 billion in technologies that would enhance NATO's defences. Portal Biotech uses an AI-backed technology with biological sensors that can work at the single molecule level on-site, giving results within hours. "It's for everything from measuring diseases to better pandemic prevention ... you can take this out of large labs with long turnaround times and into the field," CEO Andy Heron told Reuters. Heron said the company's instruments can detect any pathogen and can be used for continuous monitoring of anything from a field to water supply. "It allows you not just to detect what you did know was out there, but it allows you to detect what you didn't know," he said. Beyond biosecurity, Portal Biotech expects its portable equipment to aid in drug discovery and precision medicine. The company's investors include Earlybird Venture Capital, Science Creates VC, Pillar VC, 8VC, We VC and British Business Bank. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data